已收盤 09-21 16:00:00 美东时间
0.000
0.00%
Democrats warn of health care crisis and criticize Republican and Trump for government shutdown, prioritizing politics over protecting Americans' coverage.
10-01 13:55
Radiopharm Theranostics received a positive recommendation from the DSMC to advance 177Lu-RAD202 to the next dose level of 75mCi in the Phase 1 'HEAT' trial for HER2+ advanced solid tumors. The first cohort treated with 30mCi showed positive safety and pharmacokinetic data, supporting acceleration to the second cohort. The company aims to share data from the first two cohorts by end-2025. RAD202, a radiopharmaceutical targeting HER2 expression, h...
10-01 12:00
Strengthens North America Platform and Positions for Further Growth RENTON, Wash., Sept. 2, 2025 /PRNewswire/ -- Radiant Logistics, Inc. (NYSE American: RLGT), a leading provider of technolo...
09-03 04:05
An announcement from Music Broadcast Ltd. ( ($IN:RADIOCITY) ) is now available....
08-27 02:03
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its participation in the upcoming
08-26 04:02
Radico Khaitan Limited ( ($IN:RADICO) ) just unveiled an update. Radico Khaitan...
08-17 17:03
An update from Praxis Precision Medicines ( ($PRAX) ) is now available. On Augu...
08-04 21:18
The first readout from Guardant's research collaboration with the Parker Institute for Cancer Immunotherapy (PICI) shows Guardant Reveal detected responses to immunotherapy across multiple tumor types and identified
07-29 20:09
Radiopharm Theranostics announced financial results for FY2025 and provided updates on its pipeline. Key highlights include: - On track to complete enrollment of first two cohorts for RAD204 at 60mCi dose. - Initiated Phase 1 HEAT trial for RAD202 targeting HER2-positive tumors. - FDA granted Fast Track Designation for RAD101 to assess brain metastases. - Secured supply agreements for key radioisotopes and expanded clinical trials. - Y...
07-29 11:30
Radiopharm Theranostics has appointed Dr. Oliver Sartor, a leading medical oncologist specializing in prostate cancer and radiopharmaceutical therapies, to its Scientific Advisory Board. Dr. Sartor, who serves at the Mayo Clinic, has contributed significantly to the field with over 500 publications and pivotal FDA-approved therapies. His expertise will support the company's oncology radiopharmaceutical pipeline development.
07-22 12:00